ADAM Metalloproteinases as Potential Drug Targets

(E-pub Ahead of Print)

Author(s): Caterina Camodeca, Doretta Cuffaro, Elisa Nuti*, Armando Rossello.

Journal Name: Current Medicinal Chemistry

Submit Manuscript
Submit Proposal


The ADAMs, together with ADAMTSs and snake venom metalloproteases (SVMPs), are members of the Adamalysin family. Differences in structural organization, functions and localization are known and their domains, catalytic or non-catalytic, show key roles in the substrate recognition and protease activity. Some ADAMs, as membrane-bound enzymes, show sheddase activity. Sheddases are key to modulation of functional proteins such as the tumor necrosis factor, growth factors, cytokines and their receptors, adhesion proteins, signaling molecules and stress molecules involved in immunity. These activities take part in the regulation of several physiological and pathological processes including inflammation, tumor growth, metastatic progression and infectious diseases. On these bases, some ADAMs are currently investigated as drug targets to develop new alternative therapies in many fields of medicine. This review will be focused on these aspects.

Keywords: metalloendopeptidases, ectodomain shedding, adhesion molecules, hydroxamate inhibitors, zinc-binding group, small molecules

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867325666180326164104
Price: $95

Article Metrics

PDF: 10